Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension

NCT04846426 — Terminated, 67 participants, Novoic Limited

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

A Study to Evaluate the Ability of Speech- and Language-based Digital Biomarkers to Detect and Characterise Prodromal and Preclinical Alzheimer's Disease in a Clinical Setting - FUTURE Extension Study.

Registry	NCT04846426, acronym AMYPRED-FUTURE
Status	Terminated - Study only continued to 2 year follow-up.
Study type	Observational
Enrollment	67 (Actual)
Sponsor	Novoic Limited (Industry)
Conditions	Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Dates	start 2020-11-19, primary completion 2022-12-02, completion 2024-06-07, first posted 2021-04-15, last updated 2024-06-14
Locations	4 sites in United Kingdom

-Summary

The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in PACC5 between baseline and +12 month follow up across all four Arms, as measured by the coefficient of individual agreement (CIA) between the change in PACC5 and the corresponding regression model, trained on baseline speech data to predict it. Secondary objectives include (1) evaluating whether similar algorithms can predict change in PACC5 between baseline and +12 month follow up in the cognitively normal (CN) and MCI populations separately; (2) evaluating whether similar algorithms trained to regress against PACC5 scores at baseline, still regress significantly against PACC5 scores at +12 month follow-up, as measured by the coefficient of individual agreement (CIA) between the PACC5 composite at +12 months and the regression model, trained on baseline speech data to predict PACC5 scores at baseline; (3) evaluating whether similar algorithms can classify converters vs non-converters in the cognitively normal Arms (Arm 3 + 4), and fast vs slow decliners in the MCI Arms (Arm 1 + 2), as measured by the AUC, sensitivity, specificity and Cohen's kappa of the corresponding binary classifiers. Secondary objectives include the objectives above, but using time points of +24 months and +36 months; and finally to evaluate whether the model performance for the objectives and outcomes above improved if the model has access to speech data at 1 week, 1 month, and 3 month timepoints.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Arm 1: MCI amyloid positive			* Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia * Positive amyloid PET or amyloid CSF status. * MMSE 23-30 (inclusive)
Arm 2: MCI amyloid negative			* Non-AD Mild Cognitive Impairment (MCI) * Negative amyloid PET or amyloid CSF status. * MMSE 23-30 (inclusive)
Arm 3: CN amyloid positive			* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline * Positive amyloid PET or amyloid CSF status. * MMSE 26-30 (inclusive)
Arm 4: CN amyloid negative			* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline * Negative amyloid PET or amyloid CSF status. * MMSE 26-30 (inclusive)

+Outcome measures

Primary outcomes

The agreement between the change in the PACC5 composite between baseline and +12 months and the corresponding regression model, trained on baseline speech data, predicting in all four Arms, as measured by the coefficient of individual agreement (CIA). [1 year]: Baseline speech data is speech data collected during the first 14 days of the study for each participant.

Secondary outcomes

The agreement between changes in the PACC5 composite between baseline and +24, +36 months and the corresponding regression models, trained on baseline speech data, predicting in all 4 Arms, as measured by the coefficient of individual agreement (CIA). [3 years]
The agreement between the changes in the PACC5 composite between baseline and +12, +24, +36 months and the corresponding regression models, trained on baseline speech data, to predict them in the CN Arms (3 and 4), as measured by the CIA. [3 years]
The agreement between the changes in the PACC5 composite between baseline and +12, +24, +36 months and the corresponding regression models, trained on baseline speech data, predicting them in the MCI Arms (Arms 1 and 2), as measured by the CIA. [3 years]
The agreement between the PACC5 composite at +12, +24, +36 months and the corresponding regression models, trained on baseline speech data, predicting in all four Arms based on +12, +24, +36 month speech data, as measured by the CIA. [3 years]
The agreement between the PACC5 composite at +12, +24, +36 months and the corresponding regression models, trained on baseline speech data and +12, +24, +36 month speech data, as measured by the coefficient of individual agreement (CIA). [3 years]
The AUC, sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4). [3 years]: Converters defined as having a CDR Global score of 0.5 or more at +12, +24, +36 months.
The AUC, sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +12, +24, +36 months. [3 years]
The outcomes above where the model has access to speech data at 1 month, 3 month time points, in addition to baseline speech data. [3 years]

+Eligibility

Sex: All, ages: 50 Years to 85 Years, accepts healthy volunteers

Inclusion Criteria:

* Subjects are fully eligible for and have completed the AMYPRED (Amyloid Prediction in early stage Alzheimer's disease from acoustic and linguistic patterns of speech) study.

(See https://clinicaltrials.gov/ct2/show/NCT04828122)

* Subject consents to take part in FUTURE extension study.

Exclusion Criteria:

* Subject hasn't completed the full visit day in the AMYPRED study.

+Locations (4)

Facility	City	Country
Re:Cognition Health	Birmingham	United Kingdom
Re:Cognition Health	Guildford	United Kingdom
Re:Cognition Health	London	United Kingdom
Re:Cognition Health	Plymouth	United Kingdom

+Investigators

Emil Fristed, MSc, Principal investigator, Novoic Limited